CD4/CD8 Ratio Biomarker for Melanoma Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment strategies, particularly for melanoma, face challenges in identifying responders to immuno-oncology and targeted therapies, as existing methods lack effective biomarkers to predict treatment outcomes and optimize therapy selection.
Innovation Solution
A method involving the assessment of CD4+ immune effector cells relative to CD8+ immune effector cells to determine the likelihood of benefiting from targeted therapy combined with immuno-oncology therapy, using biomarkers such as CD4+/CD8+ ratio, tumor mutation burden, PD-L1 expression, and circulating tumor DNA to stratify patients and tailor treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer therapies (chemotherapy and radiation) are used, then cancer treatment is provided, but treatment efficacy and patient selection accuracy are insufficient
Solution Approach 1:
The patent changes the parameter used for patient stratification from traditional clinical parameters to immune cell ratio parameters (CD4+/CD8+ ratio). This parameter change enables more accurate prediction of treatment response and identifies patients who are likely to benefit from combined targeted and immuno-oncology therapies.
Solution Approach 2:
The patent introduces immune cell ratios as an intermediary biomarker that mediates between the treatment administration and the prediction of treatment response. This intermediary parameter provides a measurable indicator of patient likelihood to benefit from therapy, improving both reliability and measurement precision.
2Reliability
If combined targeted therapy and immuno-oncology therapy are administered, then treatment efficacy is improved, but patient selection and stratification become more complex
Solution Approach 1:
The patent extracts the complex patient selection process into a single key parameter - the CD4+/CD8+ immune cell ratio. By isolating this critical parameter, the patent simplifies the selection criteria while maintaining the ability to identify patients who will benefit from combined therapy, thus reducing selection complexity.
Solution Approach 2:
The patent segments patients into different treatment groups based on their immune cell ratios. This segmentation allows for simplified stratification where patients with specific ratio ranges are assigned to appropriate therapy regimens, making the complex selection process more manageable and systematic.
3Adaptability or versatility
If biomarkers are used to stratify patients, then treatment personalization is achieved, but measurement and detection complexity increases
Solution Approach 1:
The patent changes the biomarker parameters to immune cell ratios (CD4+/CD8+), which are measurable through standard flow cytometry techniques. This parameter change makes the biomarkers accessible and measurable in clinical laboratories, reducing detection complexity while maintaining treatment personalization capability.
Solution Approach 2:
The patent utilizes readily available immune cell markers that can be measured using conventional laboratory techniques rather than requiring complex or expensive specialized assays. This approach makes the biomarker detection more accessible and cost-effective, reducing the barrier to implementation.
Data Source
AI summary
The disclosure relates to the use of biomarkers for predicting the response to cancer (e.g., melanoma) treatments, for selecting a treatment for a cancer patient (e.g., using targeted therapy, e.g., using an agent targeting BRAF and/or an agent targeting MEK in combination with an immuno-oncology therapy (e.g., an anti-PD-1 therapy)), for stratifying cancer patients into different treatment groups, for treating cancer patients, and for predicting clinical outcome in cancer.